Month: May 2024

Delivery Robot Market to Surpass USD 29.80 Billion by 2031 | SkyQuest Technology

Written by Customer Service on May 20, 2024. Posted in Mergers And Acquisitions.

Westford USA, May 20, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Delivery Robot Market will attain a value of USD 29.80 Billion by 2031, with a CAGR of 25% during the forecast period (2024-2031). In the digital age, the demand for high-speed Internet access and connected devices has increased exponentially, allowing intelligent robots to gain market share. Consumers in the U.S., U.K., Canada, Europe, and other developed countries all need smart tracking systems to help them save time. For example, Starship Technologies, a global leader in these products, offers a delivery solution that integrates with a delivery partner’s website or mobile app and allows them to track and manage their fleet supply. Additionally, autonomous robotic delivery is another category that is highly appreciated by customers who prefer local delivery...

Star Equity Holdings, Inc. Announces 2024 First Quarter Financial Results

Written by Customer Service on May 20, 2024. Posted in Earnings Releases And Operating Results.

Ended the first quarter with cash and cash equivalents of $14.7 million Well positioned to expand existing businesses organically and through acquisitions Timber Technologies acquisition marks a significant step forward in growth strategy OLD GREENWICH, Conn., May 20, 2024 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, reported today its financial results for the first quarter (Q1) ended March 31, 2024. All 2024 and 2023 amounts in this release are unaudited. Following the sale of our Digirad Health business on May 4, 2023, all financial results for the 2023 reporting period, unless stated otherwise, relate to continuing operations, which currently include two divisions: Building Solutions (formerly known as Construction) and Investments. Q1 2024 Financial...

Allarity Therapeutics Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

Written by Customer Service on May 20, 2024. Posted in Public Companies.

Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”) that the Company has regained compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). This confirmation follows the Company’s successful efforts to cut operation costs and improve its balance sheet, including raising new equity and reducing outstanding liabilities. As a result, Allarity Therapeutics now meets the stockholders’ equity requirement of at least $2.5 million. Thomas Jensen, CEO of Allarity Therapeutics, stated, “We...

Gray Television Commences Cash Tender Offer for Its 5.875% Senior Notes Due 2026

Written by Customer Service on May 20, 2024. Posted in Public Companies.

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” the “Company,” “we,” or “our”) (NYSE: GTN) announced today the commencement of an offer to purchase for cash (the “Tender Offer”), subject to certain terms and conditions, any and all of its outstanding 5.875% Senior Notes due 2026 (the “Notes”). The Tender Offer is being made pursuant to the Offer to Purchase dated May 20, 2024 (the “Offer to Purchase”), which sets forth a more detailed description of the Tender Offer, including the terms and conditions thereof. Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the Tender Offer. The following table sets forth certain terms of the Tender Offer: Dollars per $1,000 PrincipalAmount of SecuritiesTitle of Security CUSIP Numbers Principal...

Gray Announces Private Offering of Senior Secured Notes

Written by Customer Service on May 20, 2024. Posted in Public Companies.

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) announced today that it intends to offer up to $1 billion aggregate principal amount of senior secured first lien notes due 2029, subject to market conditions. The offering will be exempt from the registration requirements of the Securities Act of 1933 (the “Securities Act”). In connection with the offering of notes, Gray expects to (i) incur up to $750 million of a new tranche F term loan with a maturity date in 2029, (ii) increase the aggregate commitments under its existing $625 million revolving credit facility by $55 million, resulting in aggregate commitments under the revolving credit facility of $680 million and (iii) terminate commitments under a $72.5 million tranche of the revolving credit facility maturing in 2026...

ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

Written by Customer Service on May 20, 2024. Posted in Public Companies.

AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen. Abstract: e14564. The prognostic impact of transforming growth factor beta 2 (TGFB2) mRNA levels, in conjunction with interferon-gamma receptor activation of interferon regulatory factor 5 (IRF5) and expression of CD276/B7-H3 in low-grade gliomas. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was...

Bridger Aerospace Responds to Concerns Over Politically Motivated Attacks on its Business

Written by Customer Service on May 20, 2024. Posted in Public Companies.

BELGRADE, Mont., May 20, 2024 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today responded to questions from various constituencies as a result of recent politically-motivated attacks on its business in certain media outlets. In recent weeks, candidates for political office and their allied political organizations have written disparaging articles and launched partisan attacks against the Company. They have assembled a mosaic of publicly available information, out of context corporate statements and negative legal risk factors and disclaimers to weave together an unflattering narrative in media reports regarding the financial health of Bridger. These statements highlight Bridger’s 2023...

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

Written by Customer Service on May 20, 2024. Posted in Public Companies.

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into Phase 2 in moderate Alzheimer’s disease; first patient enrolled in Phase 2 expected in Q2 2024. SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that its Safety Review Committee has cleared the Company’s cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development. NKGen’s initial “proof of concept” Phase 1 study was an open...

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Written by Customer Service on May 20, 2024. Posted in Public Companies.

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to...

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Written by Customer Service on May 20, 2024. Posted in Public Companies.

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company’s mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, unveiled key findings from its groundbreaking eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week (DDW) 2024 in Washington D.C. The...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals